In the Asia-Pacific region, MASLD is increasingly diagnosed in people who aren’t visibly overweight, a phenomenon known as lean MASLD. This highlights an important limitation of relying on BMI alone, as it isn’t a reliable indicator of liver or metabolic health, Dr Chetan, a senior hepatologist explains.

Individuals with lean MASLD may still carry significant metabolic risk, including visceral fat around the organs, insulin resistance despite a normal body weight, and genetic or ethnic predispositions that influence how fat is stored and processed. Because they may appear outwardly “healthy,” their risk is often overlooked, delaying diagnosis and appropriate care.

What the public should understand is that metabolic health can’t be judged by body size alone. A more accurate evaluation of liver risk goes beyond weight and includes waist circumference, waist-to-height ratio (a simple marker of central adiposity), blood sugar levels, lipid profile, blood pressure, and family history. Central fat distribution, rather than overall body weight, is often the stronger predictor of metabolic and liver risk.

MASLD is common, often silent, but not inevitable. Early identification, targeted risk factor management, and sustainable lifestyle choices remain the most effective tools available. With greater awareness and timely action, individuals can protect not only their liver health, but their overall metabolic wellbeing.

MASLD is closely linked to metabolic health, particularly the body’s ability to use insulin effectively. When insulin resistance develops, as seen in prediabetes and type 2 diabetes, it promotes excess fat accumulation in the liver and drives low-grade inflammation. Abnormal lipid metabolism, including high cholesterol, further compounds this process by increasing fat delivery and storage within liver cells.

This implications extend beyond the liver. Early management of insulin resistance and lipid abnormalities can slow disease progression and reduce the risk of long-term liver damage. Improving metabolic health also lowers the likelihood of cardiovascular disease, diabetes-related complications, and other chronic conditions, reinforcing why MASLD should be addressed as part of a broader systemic risk profile rather than in isolation.

Dr Chetan outlines how the liver and gut are closely connected through the bloodstream, meaning products of digestion and gut microbes can directly influence liver health. When the gut microbiome is disrupted, it may increase inflammation and alter how the liver processes fats, contributing to MASLD progression.

Emerging research suggests several everyday habits may help support a healthier gut–liver axis. These include increasing dietary fibre and plant diversity, cutting back on ultra-processed food intake, and incorporating prebiotic- and probiotic-rich foods as part of a balanced diet.

While targeted microbiome-based therapies are still under investigation, maintaining gut health through wholesome eating, regular physical activity, and adequate sleep remains a practical way to support both metabolic and liver health.

As interest in the gut-liver axis grows, many people view probiotics as a reset button for gut health. In reality, the microbiome functions as a dynamic ecosystem shaped daily by diet, metabolic status, sleep, physical activity, medications, and overall health.

In MASLD and metabolic disease, probiotics may offer modest benefits in selected individuals, including small improvements in inflammatory markers or liver enzymes in some studies. However, they don’t reverse fibrosis, replace weight reduction, or resolve insulin resistance. The overall effect size is typically incremental rather than transformative.

What is often overstated is the expectation that a capsule can correct years of metabolic dysfunction. Commercial products vary widely in strain composition, dosage, and quality control, and most aren’t personalised to an individual’s microbiome profile. There’s currently no single “best probiotic” for liver disease.

What patients can reasonably expect is that probiotics may serve as supportive therapy alongside foundational lifestyle measures. The primary drivers of microbiome health remain fibre diversity, reduced ultra-processed food intake, regular physical activity, adequate sleep, and sustained metabolic risk control.

When those foundations are prioritised, supplements may complement them. Without them, benefits are likely to be limited.

MASLD (metabolic dysfunction-associated steatotic liver disease) is far more than a liver fat issue. It’s a systemic metabolic condition that often progresses quietly, long before symptoms appear. This is why proactive screening is especially important for individuals with type 2 diabetes, obesity, high cholesterol, high blood pressure, or metabolic syndrome.

In clinical practice, a combination of tools is typically used. Ultrasound remains widely available and is useful for detecting liver fat, while FibroScan, also known as transient elastography, offers a non-invasive way to assess both fat accumulation and liver fibrosis (scarring). Simple blood tests and validated prediction scores such as FIB-4 are also commonly used to help determine whether further evaluation is needed.

For people at higher metabolic risk, repeating these assessments every one to three years can help identify early liver damage before it progresses, allowing intervention to begin while changes may still be reversible.

When screening results are described as “borderline” or even reported as normal in someone with ongoing metabolic risk, they should be interpreted cautiously rather than as definitive reassurance. Fatty liver and fibrosis are dynamic processes. A single normal ultrasound, FibroScan, or FIB-4 reflects a point in time and doesn’t remove persistent drivers such as obesity, diabetes, insulin resistance, or dyslipidaemia.

In clinical practice, borderline values require context. If metabolic risk remains active, the liver may still be vulnerable. Normal liver enzymes don’t reliably exclude fibrosis, and a low FIB-4 today doesn’t guarantee stability over time. These tools are designed to stratify risk, not provide lifetime clearance.

The appropriate approach is structured surveillance: optimise metabolic parameters, repeat non-invasive testing at defined intervals, typically every one to three years depending on overall risk burden, and consider specialist review if trends worsen. The focus shifts from asking whether damage is present to assessing whether the overall trajectory is improving or deteriorating.

For individuals at higher metabolic risk, stability isn’t simply stability, but sustained reduction of metabolic risk over time.

At present, there are no approved medications that specifically treat MASLD, which is why lifestyle change remains the foundation of care. According to Dr Chetan, evidence consistently shows that sustained weight loss can significantly reduce liver fat, improve inflammation, and, in some cases, slow fibrosis progression.

The most effective approaches tend to be Mediterranean-style or whole-food dietary patterns, combined with regular physical activity and ongoing behavioural support, as these are more sustainable over time. In recent years, newer metabolic medications, including some weight-loss agents, have also shown promise in reducing liver fat and improving underlying metabolic risk factors. However, Dr Chetan emphasises that these are prescribed under medical supervision and used as part of comprehensive care rather than as stand-alone solutions.

Ultimately, long-term success depends less on any single strategy and more on setting realistic goals, regular follow-up, and support that fits into an individual’s daily life. In practice, this is often where challenges emerge.

In clinical settings, people rarely struggle because they lack information. More often, lifestyle change collides with biology, psychology, and environment. Metabolic disease isn’t simply a matter of willpower. Insulin resistance can increase hunger, stress may intensify cravings, sleep disruption alters appetite regulation, and demanding schedules reduce consistency. Expecting motivation alone to overcome these physiological and environmental pressures is unrealistic.

Another common barrier is perfectionism. Patients may begin with highly restrictive diets or excessive exercise, and when progress plateaus or life circumstances shift, they interpret this as failure and disengage. Plateaus are biologically expected in metabolic adaptation.

Social and cultural environments also influence outcomes. Food is social, emotional, and habitual. Sustainable change requires practical adaptation rather than restriction alone. If a strategy doesn’t integrate into daily life, long-term adherence becomes difficult.

When progress slows, the response should be recalibration rather than self-blame. Reassessing sleep, stress levels, medication adherence, dietary patterns, and physical activity intensity often reveals modifiable barriers. Shifting the focus from rapid weight reduction to metabolic consistency may improve sustainability. In selected high-risk individuals, adjunctive metabolic pharmacotherapy may be considered under medical supervision.

A more constructive approach shifts the question from “Why is weight not changing?” to “What barrier is currently outweighing the plan?” Focusing on identifying and addressing barriers, rather than attributing blame, often leads to more sustainable progress.

Long-term success in MASLD depends on consistency over time. It’s built on sustainable adjustments, regular follow-up, and preventing regression rather than short-term gains.